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Protein kinases are key mediators of cellular sig-
naling, and therefore, their activities are tightly con-
trolled. AGC kinases are regulated by phosphoryla-
tion and by N- and C-terminal regions. Here, we
studied the molecular mechanism of inhibition of
atypical PKCz and found that the inhibition by the
N-terminal region cannot be explained by a simple
pseudosubstrate inhibitory mechanism. Notably, we
found that the C1 domain allosterically inhibits
PKCz activity and verified an allosteric communica-
tion between the PIF-pocket of atypical PKCs and
the binding site of the C1 domain. Finally, we devel-
oped low-molecular-weight compounds that bind to
thePIF-pocket andallosterically inhibit PKCzactivity.
Thiswork establishes acentral role for thePIF-pocket
on the regulation of PKCz and allows us to envisage
development of drugs targeting the PIF-pocket that
can either activate or inhibit AGC kinases.
INTRODUCTION
From bacteria to vertebrates, protein phosphorylation plays an
important role in the transmission of intracellular signals (Pawson
and Scott, 2005). Protein kinases, which catalyze phosphoryla-
tion events, have evolved stringent mechanisms for the regula-
tion of their intrinsic activities and their ability to phosphorylate
specific downstream substrates (Biondi and Nebreda, 2003;
Huse and Kuriyan, 2002; Shi et al., 2006). Importantly, deregula-
tion of intracellular phosphorylation can lead to human diseases
such as diabetes, cancer or neurological disorders. Thus, there
is significant interest in the development of drugs to regulate
the activity of protein kinases (Cohen, 2002).
The kinase catalytic core consists of a small N-terminal lobe
and a large C-terminal lobe. The ATP-binding site, which is
common to all protein kinases and the target of most drug devel-Chemistry & Biology 18, 1463–147opment programs against kinases, is located in between these
two lobes (Knighton et al., 1991a) (Figure 1A). Protein kinases
are themselves also regulated by phosphorylation, and mem-
bers of the AGC kinase group share a mechanism of activation
involving phosphorylation at three distinct sites: the activation
loop (within the catalytic core) as well as the Z/turn-motif and
the hydrophobic motif (HM) within a C-terminal extension that
is only conserved in this family of protein kinases (Parker and
Parkinson, 2001). In active AGC kinases, the HM binds to
a specific pocket on the small lobe, which is defined by helices
a-B and a-C and strands b-4 and b-5 (Knighton et al., 1991b;
Yang et al., 2002a). We first characterized the regulatory role of
the HM and its binding site in PDK1 and termed this site the
‘‘PIF-binding pocket’’ (Biondi et al., 2000). Notably, the binding
of a polypeptide derived from the C-terminal HM of PRK2 (PIF-
tide) activated PDK1 in vitro, whereas mutations of residues at
the PIF-pocket of PDK1 rendered mutant proteins with higher
activity (Biondi et al., 2000), suggesting that the PIF-pocket
was a key regulatory site for PDK1. It is now understood that
many AGC kinases share a similar molecular mechanism of
activation comprising HM phosphorylation and binding of the
phospho-HM to the PIF-pocket, stabilizing the active structure
of the kinase catalytic domain (Biondi et al., 2000; Fro¨din et al.,
2002; Pearce et al., 2010; Yang et al., 2002b). Thus, the PIF-
pocket is a key regulatory site for the molecular mechanism of
activation of a large set of AGC kinases.
Interestingly, we and others were able to develop small com-
pounds reversible activators of PDK1 (Engel et al., 2006; Hindie
et al., 2009; Stockman et al., 2009; Stroba et al., 2009; Wei et al.,
2010) and provided crystallography and solution data on the
binding site and conformational change that prompted the
activation (Hindie et al., 2009). A first hint that the PIF-pocket
could also transduce the inhibition of PDK1 was the finding that
a PDK1 protein mutated at the PIF-pocket residue Thr148 (PDK1
[Thr148Val]) was not activated but inhibited by PIFtide in vitro
(Engel etal., 2006).More recently,mutationofPIF-pocket residues
to Cys and interrogation with Cys-containing fragment library of
compounds allowed the identification of activators and inhibitors
of PDK1 via disulfide covalent trapping of the fragments to the3, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1463
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Figure 1. Molecular Mechanism of Regula-
tion of PKCz by N-Terminal Domains
(A) Structure of the catalytic core of PKCz (model
based on PKCi structure, PDB code 1ZRZ) (Mes-
serschmidt et al., 2005).
(B) Schematic overview of PKC isoforms indicating
the different domains present in the classical,
novel and atypical PKCs (C2, C2 domain; PSR,
pseudosubstrate region; C1, C1 domain; PB1,
PB1 domain; Cat. Domain, protein kinase catalytic
domain) and the PKCz wild-type (1-592) and
truncated versions used in this study.
(C) Interaction between PKCz and PDK1. The
N-terminal region of PKCz does not regulate the
ability of PKCz to interact with its upstream kinase
PDK1.
(D) Activity of the N-terminally truncated PKCz
constructs in the presence or absence of lipid
activators (LA) using MBP as a substrate. A sig-
nificant increase in the activity of PKCz was
observed after removal of the C1 domain. The
average of two independent experiments using
two different batches of purified deletion con-
structs is shown. The error bars indicate the
standard deviation of the averages. The specific activity of PKCz [D240] (100%) varied between 25 and 40 nmol/mgmin in different purifications. Figure S1 shows
the phosphorylation state of the enzymes shown in (D). Figure S2 shows that PKCz and PKCi proteins without a GST-tag are also similarly activated by LA.
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2011). Together, the findings open the possibility to pharmacol-
ogically target the PIF-pocket for the activation or inhibition of
PDK1 and broaden the rather poorly represented field of develop-
ment of allosteric activators of enzymes (Zorn and Wells, 2010).
In spite of the importance of protein kinases for cells, health,
and disease, the molecular mechanistic detail of protein kinase
regulation remains largely unknown, partly because very few
full-length protein kinases have been crystallized. Recently, the
full-length PKBa/Akt1 was crystallized in the presence of an allo-
steric inhibitor that requires the N-terminal pleckstrin-homology
(PH) domain for its effective inhibition (Wu et al., 2010). The
activity of protein kinase C (PKC) isoforms is also regulated by
N-terminal domains (Hurley et al., 1997; Newton, 2010; Rosse
et al., 2010). The pseudosubstrate region (PSR) blocks the
substrate binding site and keeps the protein unable to phosphor-
ylate substrates, whereas the binding of activating second
messengers to other N-terminal domains release the pseudo-
substrate inhibition exposing the substrate binding site and
allowing the kinase to phosphorylate substrates. PKC isoforms
differ in the identity of the domains present within the N-terminal
region (Figure 1B). Although classical and novel PKCs possess
a C2 domain and two C1 domains (C1A and C1B), atypical
PKCs (z and i/l isoforms) do not have a C2 domain and have
only one C1 domain. On the other hand, atypical PKCs possess
a PB1 domain, which is absent in all other PKC isoforms.
All PKC isoforms contain a C1 domain preceded by the PSR.
The binding of the PSR between the small and large lobes of the
catalytic domain as if it were a substrate must position the C1A
domain (in classical and novel PKCs) and the unique C1 domain
(in atypical PKCs) directly adjacent to the peptide substrate
binding site. A major step forward in the understanding of the
molecular mechanism of regulation of PKCs was the publication
of the crystal structure of full-length PKCbII (Leonard et al.,
2011). The structure unveils the position of the C2 domain and1464 Chemistry & Biology 18, 1463–1473, November 23, 2011 ª2011the interactions of the C1B domain with the catalytic domain.
The catalytic domain structure appears to be only partially active
because the C1B domain sequesters a Phe residue (Phe629,
part of a conserved NFD sequence) that frequently forms part
of the ATP-binding site in active structures of AGC kinases.
However, the role of the C1B domain-NFD interaction in the
mechanism of regulation of the whole PKC family is not clear
because atypical PKCs only have one C1 domain, which is
equivalent to the C1A domain. It is also currently accepted that
the PIF-pocket and the helix a-C do not play a role in the regula-
tion of PKCs (Leonard et al., 2011).
Most of the studies on the regulation of PKCs have been based
on classical PKCs. Atypical PKCs are expected to follow a similar
general mechanism of inhibition of activity, where an N-terminal
PSR binds to the active site and blocks protein substrate binding
(Newton, 2010). However, in contrast to classical PKCs that are
activated by the binding of diacylglycerol and Ca2+ to the C1 and
C2 domains, atypical PKCs are regulated by a PB1 domain,
which is known to be involved inmodular protein-protein interac-
tions (Ito et al., 2001), and by one atypical C1 domain (Colo´n-
Gonza´lez and Kazanietz, 2006) whose function is not clear but
that could mediate the binding to lipids and reverse the pseudo-
substrate mediated inhibition (Hirai and Chida, 2003; Mu¨ller
et al., 1995; Nakanishi and Exton, 1992). In either case, it is
reasonable to expect that the common aspects of the molecular
mechanism of regulation of all PKC isoforms are based on the
common features present in the N-terminal region: the PSR
and its contiguous C1 domain.
In the present work, we studied the molecular mechanism of
regulation of the atypical PKCz and found that the inhibition by
the N-terminal region cannot be explained by a simple pseudo-
substrate inhibitory mechanism. We also unexpectedly found
that the inhibition of the kinase activity was directly mediated by
the C1 domain. Moreover, we uncovered an unexpected role
of the PIF-pocket in the regulation of atypical PKCs. Finally, weElsevier Ltd All rights reserved
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compounds that, binding to the PIF-pocket of PKCz, can allosteri-
cally inhibit its activity. Together, the present work provides
evidence that the PSR and its adjacent C1 domain act in concert
both for the allosteric inhibition and activation of atypical PKCs,
whereas the PIF-pocket is central to the allosteric inhibition.
RESULTS
The Role of N-Terminal Domains in the Regulation
of PKCz
Substrates of PDK1 often regulate their activation-loop phos-
phorylation by modulating their ability to interact with the
upstream kinase, PDK1 (Leslie et al., 2001). To study the mech-
anism of PKCz regulation, we first tested whether the N-terminal
regions mediate or regulate the interaction of PKCz with PDK1.
Deletion of the N-terminal domains (Figure 1B) did not signifi-
cantly affect the interaction with PDK1, indicating that they do
not play a major role in regulating the interaction (Figure 1C).
We then measured the activity of these N-terminally truncated
PKCz constructs using ATP [g32P] and MBP as substrates.
Because the surrogate substrate MBP is not a physiological
substrate, it is not expected to induce specific conformational
changes in PKCz. Therefore, this assay should provide a direct
measure of the proportion of PKCzmolecules that have an active
conformation in solution. Full-length PKCz (1-592) had low basal
activity and was activated by the lipid activator (LA) phosphati-
dylserine (Figure 1D). GST-PKCz [D98], which lacks the PB1
domain, had increased activity. However, this truncated
construct also had increased phosphorylation in the activation-
loop, suggesting that the increase in specific activity may be
due, at least in part, to an indirect effect of the slightly higher level
of phosphorylation (see Figure S1 available online). Interestingly,
we observed that GST-PKCz [D129], which also lacked the PSR,
did not exhibit a major increase in basal activity as compared to
GST-PKCz [D98] (Figure 1D). This was surprising because a
simple model of pseudosubstrate inhibition would predict a
high increase in activity when the pseudosubstrate segment is
removed. Finally, we observed that GST-PKCz [D129] was not
activated by LA, indicating that the pseudosubstrate region
was important for the activation by lipids. This was also unex-
pected because the C1 domain (but not the pseudosubstrate
region) was thought to be primarily responsible for lipid binding
and activation. Notably, we found that a construct of PKCz
also lacking the C1 domain, GST-PKCz [D180], had increased
basal activity (Figure 1D), indicating that the C1 domain, in the
absence of the PSR, participated in the inhibition of PKCz basal
activity. Altogether, the above data were not compatible with a
simple model of pseudosubstrate-mediated inhibition of PKCz
activity. Rather, the results suggested that the C1 domain in-
hibited PKCz basal activity independently of the PSR, and that
the PSR was required for the LA-mediated activation of PKCz.
Furthermore, our data are consistent with the possibility that
the C1 domain could allosterically inhibit PKCz.
The Effect of the Pseudosubstrate Region
on the Stability of PKCz
The results described above were puzzling because they did not
reveal a central role for the PSR in the inhibition of PKCz. There-Chemistry & Biology 18, 1463–147fore, we next examined the role of the PSR in PKCz. The pseudo-
substrate region of PKCs comprises a high number of positively
charged residues. To study the role of the PSR of PKCz, we
prepared a PKCz construct (PKCz [7Arg/Lys-Ala]) that had
Arg116, Arg117, Arg120, Arg121, Arg123, Lys124, and Arg127
residues within the pseudosubstrate region mutated to Ala
(KSIYRRGARRWRKLYRAN; mutated residues underlined).
PKCz [7Arg/Lys-Ala] was significantly less stable in temperature
shift experiments than the wild-type protein (Figure 2A). The
stability data indicated that the positively charged residues
within the pseudosubstrate region interacted with other regions
of the protein, providing stability. Interestingly, the wild-type
protein was also less stable in the temperature shift assay
when the incubation was performed in the presence of lipid acti-
vators (Figure 2B), suggesting that the binding of lipids to the
wild-type protein reduced interactions that both inhibited and
stabilized the protein. The loss of stability may be due to loss
of interactions involving the different N-terminal regulatory
regions of PKCz (PB1 domain, pseudosubstrate or C1 domain).
However, in parallel experiments, PKCz [7Arg/Lys-Ala] did not
lose any further stability in the presence of lipids (Figure 2C), indi-
cating that the pseudosubstrate region, and not the PB1 domain
or the C1 domain, mediated the LA-dependent loss of thermal
stability. Together, the data suggested that specific interactions
mediated by the positively charged residues within the pseudo-
substrate segment were responsible for the decreased stability
in the presence of lipid activators. The above data are consistent
with the existence of an intramolecular interaction between the
PSR and the catalytic domain, which is released upon the
binding of lipids.
The Effect of PSRtide on the Activity of PKCz
We also studied the specific activity of wild-type and N-termi-
nally truncated mutants of PKCz using a polypeptide corre-
sponding to the pseudosubstrate region of PKCz as a substrate,
where Ala 119 is replaced by Ser (PSRtide) (House and Kemp,
1987). In contrast to MBP, this substrate is derived from a region
of PKCz that may prompt direct or indirect specific interactions
with its catalytic core to inhibit PKCz. The full-length PKCz
protein phosphorylated PSRtide very efficiently with a specific
activity of 60–80 nmol/mg min (Figure 3A), supporting the idea
that the pseudosubstrate region could indeed bind to the active
site of PKCz. Notably, the LA did not increase the activity of
PKCz toward this substrate, suggesting that the binding of
PSRtide to PKCz overcame its mechanism of inhibition. More-
over, in sharp contrast to the results using MBP as the substrate
of the reaction, the truncated mutants did not have increased
activity in comparison to full-length PKCz when PSRtide
was used (Figures 3A and 3B). A similar difference between
MBP and PSRtide was observed using 1-587 atypical PKCi iso-
form and PKCz (1-592) produced in insect cells with a 6xHis-tag
and purified to homogeneity (Figure S2) indicating that the effect
was not due to the GST fusion and that it was common to
both atypical PKC isoforms. However, the GST-PKCz [D129]
construct, which included the C1 domain but not the pseudo-
substrate region, had significantly lower specific activity than
all other constructs tested (Figures 3A and 3C; Figure S2). This
result indicated that in GST-PKCz [D129], the inhibitory effect
of the C1 domain could not be reversed by PSRtide. Because3, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1465
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Figure 3. The Effect of PSRtide on the Activity of PKCz
(A) The activity of GST-PKCz wt and deletion constructs was measured using
100 mM of PSRtide as the substrate of the reaction in the presence (gray
columns) or absence (white columns) of 100 ng phosphatidyl serine (LA).
(B and C) Schematic models representing how PSRtide overcomes the allo-
steric inhibition of PKCz (1-592) and not PKCz [D129]. The model represents
the C1 domain interacting with the catalytic domain (yellow) and allosterically
affecting the active site (round shape). Release of the allosteric inhibition by the
C1 domain allows the active site to stabilize in an active conformation (angular
shape). (B) PKCz (1-592) in the presence of PSRtide had high basal activity and
was not further activated by LA, similarly to PKCz [D240], which is comprised
of only the catalytic domain of PKCz. Themodel represents that when PSRtide
competes and displaces the PSR from the PKCz active site, it also displaces all
inhibition by N-terminal domains. (C) A model explaining the effect of PSRtide
on PKCz [D129]. PKCz [D129], which lacks the PSR, had much lower activity
than the other constructs, indicating that even in the presence of PSRtide,
PKCz [D129] remained significantly in an inactive conformation. Together, the
resulting model suggests that the PSR and C1 domain act in concert to inhibit
PKCz and that the displacement of PSR is also coupled to the release of the
inhibition by its contiguous C1 domain. Figure S3 represents models consis-
tent with the results obtained with the different constructs of PKCz.
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Figure 2. Thermal Stability of PKCz and PKCz [7R/K-A]
The wild-type (wt) GST-PKCz (B) or the GST-PKCz [7Arg/Lys-Ala] (7R/K-A)
mutant (,) were incubated in the presence (closed symbols d,-) or absence
(open symbols B, ,) of lipid activator (LA), incubated for 2 min at the indi-
cated temperatures and assayed for the remaining protein kinase activity
at 24C using MBP as a substrate. The activity of PKCz or PKCz [7R/K-A]
obtained by incubation at 24C was set as 100%.
(A) PKCz [7R/K-A] was significantly less stable during 2 min temperature shifts
than PKCz wt.
(B) The presence of LA destabilized PKCz wt.
(C) PKCz [7R/K-A] did not lose further protein stability in the presence of lipids,
indicating that the pseudosubstrate regionmediated the LA-dependent loss of
thermal stability. The assay shown was performed in triplicate with similar
results obtained in two separate experiments. The specific activity of the
enzymes shown were 14–15 nmol/mg min.
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1466 Chemistry & Biology 18, 1463–1473, November 23, 2011 ª2011our data indicated that the PSR indeed occupied the substrate
binding site, this result further confirmed that the C1 domain
inhibition was allosteric and not the result of simple inhibition
by competition for the substrate binding site. In all PKC isoforms,
the PSR is directly linked to a C1 domain (C1A domain in
classical PKCs). Therefore, the position of the C1 domain and
its allosteric regulatory site must be located along a region that
comprises the helix a-C, which limits the PIF-pocket in AGC
kinases.
Allosteric Communication between the PIF-Pocket
and the C1 Interaction Site on the Catalytic Domain
of Atypical PKCs
We set up a novel assay to investigate the possible interaction
between the C1 domain constructs fused to GST and the cata-
lytic domain of atypical PKCs containing a 6xHis-tag. The assay
is based on the alphascreen technology using a donor bead
coupled to anti-GST antibodies (to bind the GST-PSR-C1 or
GST-C1 constructs derived from PKCi) and Ni-NTA acceptorElsevier Ltd All rights reserved
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Figure 4. Interaction of C1 domain constructs of PKCi with Its
Catalytic Domain
AlphaScreen interaction assay showing the binding of GST-PSR-C1 (left y
axis) or GST-C1 (right y axis) to His-PKCi D223. The interaction of both, GST-
PSR-C1 and GST-C1, with His-PKCi D223 was strongly diminished upon
addition of the HM-peptide derived from the AGC-kinase ROCK (ROCK-HM).
In contrast, the corresponding peptide phosphorylated at the HM phosphor-
ylation site (ROCK-pHM) was not able to displace the binding, indicating a high
degree of selectivity. Figure S4 shows structural models of PSR and C1
domain interaction with the catalytic core of PKCz. Figure S6 represents
a scheme on the activation of PKCz by LA.
Figure 5. The PIF-Pocket Mediates the Inhibition of PKCz
(A) A detailed view of the PIF-pocket in the small lobe of the PKCz model as
shown in Figure 1A. Key residues Gln321, Leu328, His289, and Val297 are
depicted.
(B) Activity assay of PKCz wild-type (wt) and mutants using MBP as a sub-
strate. Mutation of Val297 to Leu and His289 to Arg resulted in a protein with
higher basal activity than PKCz wild-type, suggesting that this mutant protein
partially bypassed the inhibition.
(C) Structures of the lowmolecular weight compounds described in this study.
(D) PKCz (1-592) is inhibited by PS168 (B) and PS171 (,) but not by
compound PS153 (d). The comparison between PS168, PS171, and PS153
indicates that the different substituents on the benzimidazole ring play an
important role in the mode of action of the PS168 and PS171 inhibitory
compounds and provides evidence for the specificity of their inhibition. Fig-
ure S5 shows the inhibition of full length and catalytic domain of PKCz by
PS168 and PS171 using PSRtide as a substrate of the reaction. The selectivity
for the inhibition of PKCz is shown in Table S1.
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Allosteric Regulation of Atypical PKCzbeads that bind to His-PKCi D223 (catalytic domain). The inter-
action is measured by the emission of light from the acceptor
beads that happens when the two beads are in close proximity.
GST-PSR-C1 readily interacted with His-PKCi D223. Interest-
ingly, PIFtide and the HM polypeptide derived from another
AGC kinase, ROCK (ROCK-HM, VGNQLPFIGFTYFRENL), but
not the phosphorylated peptide derived from the HM of ROCK
(ROCK-pHM, VGNQLPFIGFTYFRENL), displaced the interac-
tion (Figure 4). Notably, the construct lacking the PSR (GST-
C1) had low but measurable affinity for His-PKCi D223 and
this interaction was also displaced by the HM polypeptide
from ROCK but not by the phosphorylated HM from ROCK (Fig-
ure 4) or by an unrelated polypeptide (RTWALCGTPEYLA-
PEIILKK) derived from the activation loop of PKA (not shown),
indicating that the interaction between the C1 domain and the
catalytic domain was highly selective. The results show that
the C1 domain of an atypical PKC directly interacts with the cata-
lytic domain and suggest an allosteric communication between
the PIF-pocket and the C1 domain interaction site. The C1
domain does not possess the classical Phe-Xaa-Xaa-Phe HM
sequence and modeling does not predict that it could occupy
the hydrophobic PIF-pocket as the HM. Indeed modeling of
the pseudosubstrate into the substrate binding site, allows the
interaction of the C1 domain with the external part of the helix
a-C that is a main component of the PIF-pocket (Figure S4).
The Role of the PIF-Pocket of PKCz in the Regulation
of Its Activity
Our previous work showed that AGC kinases can be activated
by conformational changes induced in the allosteric PIF-pocket
and transmitted to the active site. After we obtained evidence
that PKCz inhibition involved an allosteric inhibition by the C1
domain, we investigated whether the PIF-pocket also partici-
pated in the mechanism of inhibition of PKCz. Mutation ofChemistry & Biology 18, 1463–147Gln321 to Glu only minimally affected the basal activity and
was activated normally by LA. However, we found that mutation
of two residues within the PIF-pocket, Val297, which is located
at the bottom of the hydrophobic pocket and His289, located
on helix a-B (Figure 5A), to Leu or Arg respectively, resulted
in a protein with consistently higher basal activity and lower
activation by LA (Figure 5B). This result was compatible with
a model in which the PIF-pocket of PKCz indeed participates
in the allosteric inhibition of the activity by the N-terminal regions
and where the PIF-pocket mutations release most of this
inhibition.
Allosteric Inhibition of PKCzwith Low Molecular Weight
Compounds Targeting the PIF-Pocket
We and others previously showed that the PIF-binding pocket
of PDK1 can be targeted by low molecular weight compounds
that activate the kinase (Engel et al., 2006; Hindie et al., 2009;
Stockman et al., 2009; Stroba et al., 2009; Wei et al., 2010).
The identification of small compounds that activated PDK1
upon binding to the PIF-binding pocket was conclusive evidence3, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1467
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conformational changes that activate PDK1. As part of our
follow-up study, we found that the compounds PS171 and
PS168 inhibited PKCz activity with <50 mM IC50 (Figures 5C
and 5D). In contrast, the related compound PS153, lacking the
phenyl ring or the Cl atoms on the benzimidazole ring, did not
inhibit PKCz, suggesting that the observed inhibition was
specific. PS171 and PS168 inhibited the basal activity of PKCz
when MBP was used as a substrate (Figure 5D), and PKCz and
PKCz[D240] were inhibited when the peptide PSRtide was
used as a substrate (Figure S5). Surprisingly, the compounds
were considerably more potent inhibitors of PKCz than of the
closely related atypical PKCi (Table S1). Selectivity profiling
also revealed that PS171 weakly activated PDK1 and that the
activation of PDK1 was specific due to the binding of PS171 to
the PIF-binding pocket. Indeed, PS171 and other compounds
from this series also led to specific activators of PDK1. For
instance, PS114 (Figure 5C) (the 5-chloro-benzimidazolyl analog
of PS171) activatedPDK13–4-foldwith AC50 = 32mM(Figure 6A).
Moreover, the crystal structures of PDK1 in complex with PS171
and PS114 confirmed that these compounds bound to the
PIF-binding pocket (Figures 6B and 6C; Table S2). These results
indicated that compounds of the 4-benzimidazolyl-3-(4-chloro-
phenyl) butanoic acid scaffold activated PDK1 but inhibited
PKCz by binding to the corresponding PIF-pockets of these
AGC kinases, respectively acting as ‘‘agonists’’ or ‘‘antagonists’’
of the protein kinase activity.
To confirm that PS168 and PS171 were indeed binding to the
PIF-pocket of PKCz, we examined whether they could also
inhibit PKCz proteins that were mutated within this pocket.
Notably, PKCz [Val297Leu; His289Arg] was resistant to inhibi-
tion by PS168 and PS171 (Figure 5D), suggesting that the
PIF-pocket mediated the inhibition by these compounds. In
addition, because PKCz [Val297Leu; His289Arg] also bypassed
the inhibition by the N-terminal domains, the results further sug-
gested that the small compounds and the N-terminal domains
used the same PIF-pocket-mediated mechanism of inhibition.
We noted above (Table S1) that atypical PKCi isoform was not
inhibited by PS168 and PS171 to the same degree as PKCz.
The two isoforms have a relatively conserved PIF-pocket but
differ in one residue at the bottom of the PIF-pocket that is
Leu328 in PKCz and Phe in PKCi. Replacement of PKCz
Leu328 for Phe, the equivalent residue in PKCi, rendered
a mutant protein that, similar to PKCi, was not inhibited by
the small compounds (Figure 6D). To obtain more conclusive
evidence for the binding site of PS168 and PS171, we mutated
the PIF-binding pocket of PDK1 by replacing eight residues
with the equivalent PKCz amino acids (Leu113Val, Ile118Val,
Ile119His, Val124Ile, Thr128Gln, Arg131Lys, Thr148Cys, and
Phe157Leu), rendering a chimera protein, PDK1-[PIF-pocket-
PKCz] (Figure 6E). Whereas PDK1 was weakly activated by
PS168 and PS171, the PDK1-[PIF-pocket-PKCz] mutant was
now inhibited by PS168, resembling the effect observed on
PKCz (Figure 6F). Thus, our data indicated that the PIF-pocket
of PKCz was the target for the small compounds that allosteri-
cally inhibited PKCz. Because the PIF-pocket also mediated
the inhibition by N-terminal domains, we conclude that the PIF-
pocket is a key site participating in the molecular mechanism
of inhibition of PKCz.1468 Chemistry & Biology 18, 1463–1473, November 23, 2011 ª2011The Effect of PS Compounds on PKCz-Dependent NFkB
Signaling in U937 Cells
Inhibition of PKCzwas postulated to be therapeutically useful for
treatment of immune and inflammatory diseases (Trujillo et al.,
2009). In this context, it was previously reported that PKCz plays
an important role in the activation of NFkB (Levy et al., 2011;
Mu¨ller et al., 1995). Preincubation of U937 cells with PS171
and PS168, but not with their inactive counterpart PS153,
blocked TNFa-induced NFkB activation with an IC50 < 50 mM
(Figure 7). A larger set of 4-benzimidazolyl-3-phenylbutanoic
acids compounds variants of PS168 and PS171 showed a
good correlation between the in vitro inhibition of PKCz activity
and the inhibition of NFkB signaling in cells (Fro¨hner et al.,
2011), providing further evidence that the cellular target is likely
PKCz. This result indicates that the PIF-pocket of PKCz is acces-
sible in vivo under physiological conditions and suggests that
equivalent allosteric effects that inhibit PKCz in vitro also inhibit
its physiological function in cells. The results therefore support
the idea that allosteric PIF-pocket drugs could act as inhibitors
of signaling pathways where AGC kinases are involved.
DISCUSSION
To catalyze specific and timely phosphorylation of substrates,
the activity of protein kinases is tightly regulated. In spite of
the importance of protein kinases in the signaling of physiolog-
ical and pathological responses, the molecular mechanisms
that operate the regulation of protein kinases remain largely
unknown. The mechanism of regulation of PKC isoforms has
been widely investigated over the years, and a general model
was established. The common aspects of the molecular mech-
anism of regulation of PKCs by N-terminal domains must be
based on common features present in all isoforms. Because all
PKC isoforms possess a PSR and an adjacent C1 domain, it is
reasonable to expect that the common mechanism of regulation
by the N-terminal domains must involve these two regions
and their interaction sites on the catalytic domain. However,
the recent crystal structure of PKCbII does not reveal the molec-
ular details of the interaction between the PSR or its contiguous
C1 domain and the catalytic core. The present work provides
new data to support a model for the molecular mechanism of
inhibition by the PSR and its contiguous C1 domain: (1), the C1
domain makes specific interactions with the catalytic domain;
(2), the C1 domain allosterically inhibits PKCz activity; (3), muta-
tions in the PIF-pocket bypass the inhibition by the N-terminal
domains; (4), HM-polypeptides displace the interaction between
the C1 domain and the catalytic domain; and (5), small com-
pounds that specifically bind to the PIF-pocket of PKCz trans-
duce conformational changes that inhibit its activity. The data
allows us to revise the model of the mechanism of inhibition of
atypical PKCz, assigning an allosteric inhibitory role to the C1
domain and a central regulatory role to the PIF-pocket. Because
the PSR and its adjacent C1 domain are common to all PKC iso-
forms, we suggest that the mechanisms described here may be
shared by the whole family.
Our data clearly disprove the existence of a simple pseudo-
substrate mechanism of inhibition in PKCz, because deletion
of the PSR did not increase the specific activity of the kinase.
Nevertheless, consistent with the accepted model, our studiesElsevier Ltd All rights reserved
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Figure 6. Binding of the Benzimidazole Compounds to the PIF-Pocket of Different AGC kinases can allosterically activate or inhibit the
kinases, acting as agonists or antagonists of the activity.
(A) Activation of PDK1 by PS114.
(B and C) Crystal structures of PDK1 in complex with the allosteric activators PS114 (B) and PS171 (C). The ring systems of both compounds are positioned
similarly in the PIF-binding pocket of PDK1. The carboxylate moiety of PS114 is unresolved and is shown in transparent white. The depicted 2Fo-Fc electron
density maps are contoured at 1s.
(D) Activity assays with PKCzmutants identify the PIF-pocket as the target site of PS168 and PS171. PS168 and PS171 (50 mM) inhibit PKCz wt but not PKCi or
PKCz proteins mutated within the PIF-pocket (PKCz [Leu328Phe] and PKCz [Val297Leu]; His289Arg).
(E) The PIF-binding pocket of PDK1 showing that mutants that mimic PKCz PIF-pocket (PDK1-[PIF-pocket-PKCz], in the figure named as PDK1[P-P-z]).
(F) PDK1[P-P-z] can no longer be activated by PS168 and PS171 (100 mM). PS168 activates PDK1 wt but inhibits PDK1[P-P-z], indicating that the replacement of
the PIF-binding pocket amino acids with those of PKCz changes the conformational transition from activation to inhibition by compounds targeting the same site.
Table S2 shows the data collection and refinement statistics for the structures shown in (B) and (C).
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domain as a pseudosubstrate and that this interaction is lost in
the presence of lipid activators. Our data further indicate that
in the absence of the PSR, the C1 domain allosterically inhibits
PKCz. Because both the PSR and the C1 domain are contiguous
in the sequence, our results suggest that the PSR and the C1
domain acted in concert at two neighboring sites, blocking the
active site and affecting the helix a-C at the PIF-pocket, to
accomplish the inhibition of PKCz (Figure S4). This result was
surprising because the current accepted models for the regula-
tion of PKCs do not describe a major role for either the C1A
domain or the PIF-pocket in the autoinhibition. However, there
is one report that shows only a small increase in specific activity
in a PKCz protein where the PSR is deleted (Le Good and Brind-
ley, 2004) and there is at least one report showing that the C1A
domain of PKCa allosterically inhibits its activity (Kirwan et al.,
2003). Therefore, it is likely that the mechanism that we have
described here is not only valid for atypical PKCs, but also for
classical PKCs and possibly for novel PKC isoforms. In protein
kinases, the protein substrate binding site faces the ATP-binding
site between the small and the large lobe (Knighton et al., 1991a;Chemistry & Biology 18, 1463–147Yang et al., 2002a). The binding of the PSR at the peptide binding
site as a pseudosubstrate determines the location of the adja-
cent C1 domain (C1A domain in classical PKCs) directly in the
proximity of the helix a-C and the activation loop. This assump-
tion is confirmed by the SAXS structure of PKCbII (Leonard et al.,
2011). The allosteric inhibition by the C1 domain is therefore con-
sistent with the idea that the C1 domain could directly interact
with residues from the helix a-C, mediating the effects on the
PIF-pocket of PKCz. The PIF-pocket can potentially mediate
its effect on the activity by altering the helix a-B and indirectly
affecting the Gly-rich loop, or by altering the helix a-C and
affecting the Glu-Lys pair interaction that helps position the
phosphates from ATP for catalysis. Alternatively, it is possible
that the C1 domain of PKCz and the C1A domain of classical
PKCs may directly disturb the formation of the helix a-C in
a manner that resembles the interaction between the PH domain
of PKB/Akt and its catalytic core (Wu et al., 2010).
Our data also provide information about the molecular mech-
anism of activation of PKCz. We found that PKCz [D129], which
lacks the pseudosubstrate region but still possesses the C1
domain, could not be activated by lipids, indicating that the3, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1469
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Figure 7. The Effect of Compounds on PKCz-Dependent NFkB
Activation
Preincubation with PS168 and PS171 inhibits PKCz-dependent NFkB acti-
vation in U937 cells (IC50 < 50 mM). In contrast, PS153, an analog compound
that is inactive in vitro, had no effect on NFkB activation by TNFa. Incubation of
the cells at each concentration of the compounds tested was performed in
triplicate. A representative experiment out of three is shown. The error bars
represent the standard deviation of the triplicates.
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allosteric inhibition of PKCz. This result further indicated that the
PSR was required for the activation of PKCz by LA. These data
are compatible with a model where the PSR and the C1 domain
are both required and act in concert to bind LA and to release the
interactions with the catalytic core that inhibit PKCz activity.
Because polypeptides derived from the PSR of PKC isoforms
can also bind to lipids (Mosior and McLaughlin, 1991), it is
possible that the concerted displacement of the interaction
may be due to the synergistic binding of phosphatidylserine to
the PSR and the C1 domain.
It was previously suggested that the helix a-C may not play an
important role in the regulation of PKC isoforms because it was
always observed as a stable helix in all PKC crystal structures
solved to date. However, we have previously also observed
the ‘‘stable’’ helix a-C in several crystal packings of PDK1,
even when hydrogen/deuterium exchange experiments revealed
that the helix a-C of PDK1 was very flexible in solution (Hindie
et al., 2009). In agreement with the hypothesis that the PIF-
pocket plays a major role in the regulation by the N-terminal
domains, hydrogen/deuterium exchange experiments on the
catalytic domain construct of atypical PKCi isoform revealed
that a polypeptide comprising the helix a-C had very high
hydrogen/deuterium exchange rates, whereas the equivalent
polypeptide of the full-length construct was highly protected
(not shown). Therefore, all our data suggest that the a-C helix
of PKCs may not be as rigid in solution as had been expected
from crystallography data alone, and that it indeed undergoes
conformational changes upon regulation by the N-terminal
domains or small compounds.
In the process of activation of AGC kinases by HM phosphor-
ylation, the HM binds to the hydrophobic PIF-pocket whereas
the phosphate binds to a neighboring phosphate-binding site
(Biondi et al., 2002). In this manner, residues of the helix a-C
and the phosphate binding site are stabilized in an active confor-1470 Chemistry & Biology 18, 1463–1473, November 23, 2011 ª2011mation, supporting increased specific activity (Hindie et al.,
2009). Phosphorylation at the Z/turn-motif site, which is also
within the C-terminal extension, supports the activity of AGC
kinases acting as a zipper, facilitating the binding of the HM to
the PIF-pocket (Hauge et al., 2007). The NFD motif that interacts
with the C1B domain of PKCbII (Leonard et al., 2011) is also part
of the C-terminal extension to the catalytic core that holds the
Z/turn-motif and HM phosphorylation sites. It is tempting to
speculate that the interaction of the C1B domain with the NFD
motif may affect the whole C-terminal region and have allosteric
effects on the PIF-pocket. However, it is not clear if such amech-
anism of regulation happens in atypical PKCs because they lack
the second C1 domain.
In the present work we defined the role of the C1 domain and
the PIF-pocket on the regulation of atypical PKCs using isolated
components. For in vitro activation of the kinase we employed
phosphatidylserine. However, this procedure did not lead to
complete activation of the full-length kinase. This could be ex-
plained by the finding that the conditions that activated atypical
PKCs in vitro (e.g., phosphatidylserine) also destabilized the
kinase. Alternatively, it is possible that in a cellular environment
other cellular factors may participate in the activation of atypical
PKCs and stabilize the active forms of the kinases. In previous
work aimed to understand the mechanism of regulation of
PKCz in cells, overexpression of different PKCz mutants led to
a complicated pattern of results where degradation of the over-
expressed proteins prompted the appearance of PKCz forms
lacking all N-terminal domains (presumably constitutively active
and lacking proper localization) whereas the specific activity of
the constructs did not always correlate with their ability to pro-
mote cellular transformation (Le Good and Brindley, 2004).
Together, we believe that the molecular events that regulate
atypical PKCs in vivo remain to be fully established and may
be best addressed with knock-in technologies.
We previously confirmed the importance of the PIF-binding
pocket for the activation of PDK1 by developing low molecular
weight compounds that activated the kinase by binding specifi-
cally to the PIF-binding pocket (Engel et al., 2006; Hindie et al.,
2009). The results of these experiments provided evidence that
the PIF-pocket on its own could mediate the conformational
changes that activate an AGC kinase by phosphorylation. In the
present work, we provide the first evidence, to the best of our
knowledge, that thePIF-pocket can also participate in themolec-
ular mechanism of inhibition of an AGC kinase. Notably, we
confirm that the PIF-pocket can transduce the inhibition of
PKCz through the use of low molecular weight compounds that,
binding to the PIF-pocket of PKCz, allosterically inhibit the kinase
in vitro and inhibit a PKCz-dependent pathway in cells in culture.
Herein, we have thoroughly evaluated the molecular mecha-
nism of inhibition of PKCz and shown that the C1 domain alloste-
rically inhibits its activity and that the PIF-pocket mediates
the allosteric inhibition of PKCz. These data complement the
understanding of the molecular mechanism of regulation of the
PKC protein kinase family as a whole. Finally, as a means to
confirm the central role for the PIF-pocket in vitro and in cells,
we describe the first low molecular weight compounds that
target the PIF-pocket and inhibit the activity of PKCz. The exact
molecular events that occur locally at the PIF-pocket and alloste-
rically at the ATP-binding site upon the interaction with the C1Elsevier Ltd All rights reserved
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However, our current work allows us to envisage the future
development of drugs that can either activate or inhibit AGC
kinases by pharmacological intervention hijacking the mecha-
nisms that nature designed as natural ‘‘ON-OFF’’ switches
located at the PIF-pocket.
SIGNIFICANCE
It was broadly accepted that PKC isoforms, like PKA, would
not be regulated by the PIF-pocket. Our work establishes
that PKCz is allosterically inhibited by the C1 domain and
that it can be allosterically inhibited by compounds that
bind to the PIF-pocket. The identification of allosteric inhibi-
tion in a PKC isoform is not a minor change in the model of
regulation of the kinase because it has very profound effects
on the potential for drug discovery to the whole family of
PKC isoforms. The regulation of the activity of protein
kinases is one example of the mechanisms used by nature
to modulate the conformation of proteins. In AGC kinases,
a widespread regulatory step is given by the folding of the
C-terminal phosphorylated HM onto the PIF-pocket,
whereas other AGC kinase-specific mechanisms of regula-
tion involve the folding of other domains (e.g., PH or C1
domains) onto the catalytic core. A key for the development
of pharmacological ON-OFF switches for AGC kinases was
the identification and characterization of a major regulatory
site, the PIF-pocket and the in-depth evaluation of the
molecular mechanism of regulation of each protein of the
group. It is tempting to speculate that the conformational
changes in a large array of proteins may also be regulated
by the folding of N- or C-terminal domains onto the regu-
lated domain. Similarly to AGC kinases, the identification
of the key pockets and regulatory sites on proteins and
protein families may then allow the more extensive develop-
ment of pharmacological ON-OFF switches. Such approach
will open the field of drug discovery to a wide range of pro-
teins, for example, to proteins that undergo conformational
changes upon post-translational modifications in regions
outside the regulated domain. Of interest, once a regulatory
site is identified, our experience here presented shows that
focused libraries of compounds to the site may lead to allo-
steric activators and allosteric inhibitors (agonists and
antagonists) of the conformational change. Altogether, the
current work completes the first example of pharmacolog-
ical ON-OFF switch to the family of protein kinases and
supports the novel field of drug development targeting key
regulatory sites for the development of modulators of con-
formational changes for research and future innovative ther-
apies for human diseases.
EXPERIMENTAL PROCEDURES
General materials and methods, the expression and purification of protein
kinases, and the synthesis and characterization of compounds are described
in the Supplemental Information.
Protein Kinase Activity Assay
The protein kinase activity assays were performed essentially as previously
described (Engel et al., 2006). The assays were done in a 96-well formatChemistry & Biology 18, 1463–147and 4 ml aliquots were spotted on P81 phosphocellulose papers (Whatman)
using an epMotion 5070 (Eppendorf). The papers were washed in 0.01%phos-
phoric acid, dried, and then exposed and analyzed using PhosphorImager
technology (FLA-9000 Starion, Fujifilm). Atypical PKC activity assays were
performed in a total volume of 20 ml containing 50 mM Tris-HCl pH 7.5,
0.05 mg/ml BSA, 0.1% (v/v) 2-mercaptoethanol, 10 mM MgCl2, 100 mM
[g32P]ATP (5–50 cpm/pmol), 0.003% Brij, 30–50 ng PKC, and MBP (10 mM)
or PSRtide (biotin-KSIYRRGSRRWRKLYRA-COOH, 100 mM) as the substrate.
After 15 min preincubation, the kinase reaction was started by addition of 6 ml
of an ATP-Mg mix. When required, lipid activator (LA) phosphatidylserine
(100 ng) or PKC lipid activator mix (Millipore, 13) was included in the preincu-
bation. Low basal activity and consistent activation of 1-592 PKCz and D98
PKCz by LA were observed when the preincubation time was started by addi-
tion of the whole mix on the enzyme.
The activity assays were performed in duplicate or triplicate (in the case of
the thermal stability assay) with <10% difference between the duplicate pairs.
The activity assays shown were repeated at least twice with similar results.
Most of the assays shown, however, were repeated multiple times with
enzymes from independent purifications with similar results. Representative
experiments are shown.
PKCz Thermal Stability Assay
To measure the thermal stability of PKCz, the activity of PKCz toward MBP in
the presence or absence of lipid activator wasmeasured after incubation of the
enzyme for 2min at different temperatures (24C, 37C, 42C, 46C, and 50C)
prior to the activity assay. The samples were then left on ice for 2 min, and 9 ml
aliquots were transferred to different tubes containing 11 ml of a solution giving
a final concentration of 50 mM Tris (pH 7.5), 0.2 mg/ml MBP, 0.003% Brij,
10 mM MgCl2, and 100 mM [g-
32P]ATP (5–50 cpm/pmol). The reaction was
stopped after 30 min by adding 5 ml of 200 mM phosphoric acid. Aliquots of
4 ml of each sample were spotted on P81 phosphocellulose papers (Whatman).
The papers were washed in 0.01% phosphoric acid, dried, exposed, and
analyzed using PhosphorImager technology (FLA-9000 Starion, Fujifilm).
PKCz-PDK1 Interaction Assay
The protein-protein interaction experiments shown in Figure 1 were performed
by cotransfection of HEK293 cells in 10 cm Petri dishes as previously
described (Dettori et al., 2009) with 5 mg of a pEBG-2T-PKCz plasmid that
encodes GST-PKCz (wild-type or truncated mutants) together with 5 mg of a
pCMV5-PDK1 plasmid that encodes myc-tagged PDK1. Forty-eight hours
posttransfection, the cells were lysed in 0.6 ml of lysis buffer. The lysates
were cleared by centrifugation at 13,000 3 g for 10 min at 4C, and 0.5 ml of
supernatant was incubated for 2 hr at 4Cwith 30 ml of glutathione Sepharose.
The beads were washed twice with lysis buffer containing 0.5 MNaCl followed
by two further washes with a buffer containing 50 mM Tris-HCl, 0.1 mM EGTA
and 0.1% b-mercaptoethanol. The beads were resuspended in 30 ml of buffer
containing 100 mM Tris/HCl (pH 6.8), 4% (w/v) SDS, 20% (v/v) glycerol, and
200 mM dithiothreitol, and the duplicates for each condition were subjected
to SDS-polyacrylamide gel electrophoresis followed by immunoblotting. Anal-
ysis and quantification of the interaction were performed with a fluorescence
infrared imager system (Fujifilm FLA 9000 Starion). Duplicates of independent
transfections and independent pull-down experiments performed in parallel
are presented.
Alphascreen Interaction-Displacement Assay
The AlphaScreen assay was performed according to the manufacturer’s
general protocol (Perkin-Elmer). Reactions were performed in a 25 ml final
volume in white 384-well microtiter plates (Greiner). The reaction buffer con-
tained 50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM dithiothreitol, 0.01%
(v/v) Tween-20, and 0.1% (w/v) BSA. A total of 50 nM of His6-tagged PKCi
D223 were mixed with 100 nM GST-C1 (PKCi 131-186) or 25 nM GST-PSR-
C1 (PKCi 100-185) in the absence or presence of unlabeled PIFtide or peptides
derived from the HM of ROCK (ROCK-HM, VGNQLPFIGFTYFRENL or
ROCK-pHM, VGNQLPFIGFT(P)YFRENL) or the activation loop of PKA
(RTWALCGTPEYLAPEIILKK). Subsequently, 5 ml of beads solution containing
nickel chelate-coated acceptor beads and glutathione-coated donor beads
was added to the reaction mix in a final concentration of 40 mg/ml for His-
PKCi D223 and GST-C1 or 20 mg/ml for His-PKCi D223 and GST-PSR-C1,3, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1471
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room temperature and the emission of light from the acceptor beads
was measured in the EnVision reader (Perkin-Elmer) and analyzed using the
EnVision manager software.
PKCz-Dependent NFkB Signaling in U937 Cells
In U937 lymphoma cells, tumor necrosis factor alpha (TNFa)-dependent
activation of NFkB is dependent on PKCz activity (Folgueira et al., 1996; Mu¨ller
et al., 1995).
U937cells were transiently transfected with a plasmid encoding luciferase
under the control of NFkB-response elements (pGL4.32 [luc2P/NF-kB-RE/
Hygro]; Promega). After serum starvation overnight, the cells were incubated
in 96-well plates with the compounds or DMSO (0.25%) for 3 hr and stimulated
with TNFa (50 ng/ml; PeproTech) for 90 min. Bright-Glo Luciferase Assay
reagent (Promega) was added, and the luciferase activity was measured using
the multilabel reader station EnVision (Perkin-Elmer).
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